Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ALGS
ALGS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALGS News
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
4d ago
stocktwits
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
4d ago
seekingalpha
Aligos Enters Exclusive License Agreement with Amoytop
4d ago
Newsfilter
Aligos Therapeutics Reports Positive Interim Results in HBV Study
5d ago
NASDAQ.COM
Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium
6d ago
Newsfilter
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
Mar 06 2026
NASDAQ.COM
Aligos Therapeutics Q4 Earnings Beat Expectations
Mar 05 2026
seekingalpha
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
Jan 08 2026
Globenewswire
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
Dec 12 2025
Globenewswire
Aligos Grants 14,100 Stock Options to New Employees as Inducement
Dec 12 2025
Newsfilter
Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025
Dec 11 2025
Newsfilter
Aligos Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Oct 17 2025
Newsfilter
Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones
Sep 17 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Aligos Therapeutics, Keeps $50 Price Target Intact
Sep 12 2025
Benzinga
Can Aligos Therapeutics (ALGS) Surge by 737.74% According to Wall Street Analysts?
Sep 08 2025
NASDAQ.COM
Sanofi Receives FDA Approval for Wayrilz in Treating Immune Thrombocytopenia
Sep 01 2025
NASDAQ.COM
Show More News
